NUVL - Nuvalent, Inc.
IEX Last Trade
82.32
-0.070 -0.085%
Share volume: 8,510
Last Updated: Thu 26 Dec 2024 08:29:49 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$82.39
-0.07
-0.08%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-1.43%
1 Month
-14.17%
3 Months
-18.21%
6 Months
4.91%
1 Year
11.24%
2 Year
190.61%
Key data
Stock price
$82.32
DAY RANGE
$81.55 - $83.02
52 WEEK RANGE
$64.32 - $113.51
52 WEEK CHANGE
$10.10
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO: James R. Porter
Region: US
Website: nuvalent.com
Employees: 40
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: nuvalent.com
Employees: 40
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations.
Recent news